Home › Funds › Bellevue Group AG › CLDX
Bellevue Group AG position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Bellevue Group AG reported holding 1,200,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$44.7M, representing 0.94% of its reported portfolio and ranking #30 among its reported holdings. Bellevue Group AG has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's CLDX position evolved
Bellevue Group AG first disclosed a stake in CLDX in Q3 2023 at 1,900,000 shares (US$52.3M). The position peaked in Q1 2024 at 2,796,615 shares, worth US$117.4M. Across 12 filings, Bellevue Group AG increased the stake 7 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 1,200,000 shares valued at US$44.7M. Notable position changes include a 27% increase in Q4 2023 (shares rose 6% over the following quarter), a 67% trim in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.90M | $52.29M | New |
| Q4 2023 | 2.42M | $95.83M | Add |
| Q1 2024 | 2.80M | $117.37M | Add |
| Q2 2024 | 2.97M | $109.98M | Add |
| Q3 2024 | 3.07M | $104.40M | Add |
| Q4 2024 | 3.07M | $77.62M | Hold |
| Q1 2025 | 3.07M | $55.75M | Hold |
| Q2 2025 | 3.31M | $67.31M | Add |
| Q3 2025 | 3.56M | $92.04M | Add |
| Q4 2025 | 3.62M | $98.26M | Add |
| Q1 2026 | 1.20M | $38.06M | Reduce |
| Q2 2026 | 1.20M | $44.65M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 43 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.32M sh · $198.07M · Q2 2026
- Deep Track Capital, LP 2.94M sh · $109.37M · Q2 2026
- Logos Global Management LP 2.10M sh · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M sh · $66.45M · Q2 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K sh · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K sh · $26.02M · Q2 2026
- ADAR1 Capital Management, LLC 619.54K sh · $23.05M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held CLDX?
Bellevue Group AG has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in CLDX?
As of Q2 2026, Bellevue Group AG holds 1.20M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $44.65M, representing 0.94% of its reported portfolio and ranking #30.
Has Bellevue Group AG been buying or selling CLDX?
In the latest 13F filing (Q2 2026), Bellevue Group AG held unchanged its position in CLDX. The position peaked in Q1 2024 at 2.80M shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.